FDA approves Arzerra in combination with chlorambucil for CLL

  • April 17, 2014

The FDA today approved the use of intravenous ofatumumab in combination with chlorambucil for patients with previously untreated chronic lymphocytic leukemia.

The combination of ofatumumab (GlaxoSmithKline) and chlorambucil is intended for patients with CLL who are not eligible for fludarabine (Fludara, Genzyme)-based therapy due to their age or comorbidities.

Full Story »

Personalize your page!

Register for Healio to get content tailored to your specialty and areas of interest. It’s FREE and only takes one minute. Register now!

More»
More»
More»
  • Health Care Update
  • ARNOLD AND PORTER SILO
  • PQRS interim claims feedback
  • 2013 PQRS interim claims feedback data now available for individual eligible professionals. Analysis by Catherine Brandon of Arnold & Porter LLP.
More »
  • Financial Planning
  • RUDZINSKI COLUMN
  • Advice for physicians
  • Be aware of important 2014 IRA updates. Analysis by Certified Financial Planner Ken Rudzinski.
More »
HemOnc Today